BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 7747649)

  • 1. Treatment of gastroesophageal reflux: the role of proton pump inhibitors.
    Schulman MI; Orlando RC
    Adv Intern Med; 1995; 40():273-302. PubMed ID: 7747649
    [No Abstract]   [Full Text] [Related]  

  • 2. [Lansoprazol].
    Ponce J; Nos P
    Gastroenterol Hepatol; 1995 Feb; 18(2):101-9. PubMed ID: 7621274
    [No Abstract]   [Full Text] [Related]  

  • 3. [Cost-effectiveness of the treatment of reflux esophagitis: proton pump inhibitor versus histamine-2-receptor antagonist].
    Habu Y; Oyasu K; Wakamatsu T; Sumitomo Y; Kiyota K; Inokuchi H; Kawai K
    Nihon Rinsho; 2000 Sep; 58(9):1881-5. PubMed ID: 11004820
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Comparison between histamine H2-blocker and proton pump inhibitor on the effects of initial treatment in reflux esophagitis].
    Harasawa S
    Nihon Rinsho; 2000 Sep; 58(9):1847-52. PubMed ID: 11004814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The medical management of reflux esophagitis. Role of antacids and acid inhibition.
    Sontag SJ
    Gastroenterol Clin North Am; 1990 Sep; 19(3):683-712. PubMed ID: 1977703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+/K(+)-ATPase inhibitor: a controlled, double-blind study. Lansoprazole Study Group.
    Feldman M; Harford WV; Fisher RS; Sampliner RE; Murray SB; Greski-Rose PA; Jennings DE
    Am J Gastroenterol; 1993 Aug; 88(8):1212-7. PubMed ID: 8101695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical treatment of gastroesophageal reflux disease: options and priorities.
    Thomson AB
    Hepatogastroenterology; 1992 Feb; 39 Suppl 1():14-23. PubMed ID: 1349550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. The Dutch Reflux Study Group.
    Festen HP; Schenk E; Tan G; Snel P; Nelis F
    Am J Gastroenterol; 1999 Apr; 94(4):931-6. PubMed ID: 10201459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. pH, healing rate, and symptom relief in patients with GERD.
    Huang JQ; Hunt RH
    Yale J Biol Med; 1999; 72(2-3):181-94. PubMed ID: 10780580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic approaches to healing esophagitis.
    Boyce HW
    Am J Gastroenterol; 1997 Apr; 92(4 Suppl):22S-27S; discussion 27S-29S. PubMed ID: 9127623
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lansoprazole prevents recurrence of erosive reflux esophagitis previously resistant to H2-RA therapy. The Lansoprazole Maintenance Study Group.
    Sontag SJ; Kogut DG; Fleischmann R; Campbell DR; Richter J; Haber M
    Am J Gastroenterol; 1996 Sep; 91(9):1758-65. PubMed ID: 8792694
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stability of gastric secretory inhibition during 6-month treatment with omeprazole in patients with gastroesophageal reflux disease.
    Tefera S; Hatlebakk JG; Berstad A
    Am J Gastroenterol; 2001 Apr; 96(4):969-74. PubMed ID: 11316213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Duodenal ulcer and gastroesophageal reflux disease today: long-term therapy--a sideways glance.
    Bardhan KD
    Yale J Biol Med; 1996; 69(3):211-24. PubMed ID: 9165690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton pump inhibitors: cost-effective agents for management of reflux-induced esophagitis.
    Gregor JC
    Am J Manag Care; 2000 Aug; 6(8):934-5. PubMed ID: 11186505
    [No Abstract]   [Full Text] [Related]  

  • 15. Clinical review of lansoprazole.
    Lockhart SP
    Br J Clin Pract Suppl; 1994; 75():48-55; discussion 56-7. PubMed ID: 8060802
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Role of ranitidine in the treatment of gastroesophageal reflux and its complications].
    Mainguet P
    Rev Med Suisse Romande; 1995 Oct; 115(10):781-8. PubMed ID: 7501930
    [No Abstract]   [Full Text] [Related]  

  • 17. Long-term management of gastroesophageal reflux disease and its complications.
    Richter JE
    Am J Gastroenterol; 1997 Apr; 92(4 Suppl):30S-34S; discussion 34S-35S. PubMed ID: 9127624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antisecretory drugs, Helicobacter pylori infection and symptom relief in GORD: still an unexplored triangle.
    Scarpignato C
    Dig Liver Dis; 2005 Jul; 37(7):468-74. PubMed ID: 15893968
    [No Abstract]   [Full Text] [Related]  

  • 19. [Drug therapy of reflux disease].
    Pikkarainen P
    Duodecim; 2000; 116(17):1885-90; quiz 1891, 1866. PubMed ID: 12001644
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of Helicobacter pylori eradication on the anti-secretory efficacy of lansoprazole in gastroesophageal reflux disease patients.
    Giral A; Celikel CA; Ozdogan O; Tözün N; Ulusoy NB; Kalayci C
    J Gastroenterol Hepatol; 2005 Dec; 20(12):1886-91. PubMed ID: 16336449
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.